Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Adierazpen geografikoek jatorrizko produktu baten izena eremu geografiko batetik babesten dute, eta adierazpen horri esker kalitate, ospe edo beste ezaugarri jakin batzuk ditu. Ezagutu zer diren, zein den erregistratzeko prozedura eta zer onura dituzten.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
223
resultados
Última actualización
02/11/2026 [07:28:00]
Resultados 150 a 175 de 223
Resumen de: US20260325448A1
0000 The present invention provides cationic lipids and lipid nanoparticle formulations comprising these lipids, alone or in combination with other lipids. These lipid nanoparticles may be formulated with nucleic acids to facilitate their intracellular delivery both in vitro and for therapeutic applications. The present invention also provides methods of chemical synthesis of these lipids.
Resumen de: US20260325564A1
Compositions including a nucleotide sequence as set forth in SEQ ID NO: 1 and/or having 95% homology to SEQ ID NO:1, more preferably having 99% homology to SEQ ID NO: 1 wherein each uracil loci in SEQ ID NO: 1 has been substituted with 5-Methoxyuridine (5 MOU) and/or N1-Methylpseudouridine (N1). A method of treating and/or preventing human erectile dysfunction in a subject in need thereof by (a) contacting human penile cells with a composition having a nucleotide sequence as set forth in SEQ ID NO: 1 and/or having 95% homology to SEQ ID NO: 1, more preferably having 99% homology to SEQ ID NO: 1 wherein each uracil loci in SEQ ID NO: 1 has been substituted with 5-Methoxyuridine (5 MOU) and/or N1-Methylpseudouridine (N1).
Resumen de: US20260325617A1
0000 Provided herein are compositions including a liposome including Compound A (A), wherein n is 1 (IMM60), 2 (IMM70), or 3 (IMM80), or a salt, ester, solvate, or hydrate thereof, and two or more lipids or salts thereof; and uses thereof, including methods of stimulating an immune response. Also provided herein are liposomes comprising at least one therapeutic agent and a phospholipid bilayer comprising at least two phospholipids selected from 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-distearoyl-sn-glycero-3-phospho-rac-glycerol (DSPG), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), and 1,2-dipalmitoyl-sn-glycero-phosphor-rac-(1-glycerol)(DPPG), wherein the phospholipid is substantially devoid of cholesterol, plant sterols, and polyethylene glycolated lipids (PEG lipids).
Resumen de: US20260325487A1
0000 A composition comprising 17-AAG and staurosporine for use in the treatment of melanoma, non-small cell lung cancer, pancreatic cancer, mammary gland tumours or gliomas, and a stable polymer-lipid nanoparticle for drug binding and delivery, consisting of a core containing polylactic-co-glycolic acid (PLGA) and polyvinyl alcohol (PVA) and a core envelope containing a mixture of lipids: 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DDPC), cholesterol and the ammonium salt 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-amino (polyethylene glycol)-2000 (DSPE-PEG(2000)NH2J.
Resumen de: US20260325458A1
An object of the present invention is to provide a lipid particle that can be produced without using a PEG-modified lipid, or that exhibits higher drug effects, safety, or stability than those of a lipid particle produced using a PEG-modified lipid; or that has immunokinetics different from those of a lipid particle produced using a PEG-modified lipid.A lipid particle comprising an ionized lipid, a phospholipid, and a sterol as lipid components of the lipid particle, and a modified polysaccharide containing a hydrophobic group.
Resumen de: WO2026218598A1
A dynamic covalent bond-based hydrogel for a black phosphorus-loaded liver cancer drug, and a preparation method therefor and an application thereof. The dynamic covalent bond-based hydrogel for a black phosphorus-loaded liver cancer drug comprises black phosphorus, doxorubicin, 4-arm PEG benzaldehyde and 4-arm PEG cyanopropyl. A two-dimensional nanomaterial black phosphorus is combined with a dynamic covalent bond-based hydrogel in order to deliver a drug, thereby constructing a composite drug delivery platform. In combination with drug therapy, photothermal therapy and environmentally responsive autonomous drug release, the BP is used as a photothermal agent and a drug carrier, and the hydrogel is used as a controllable release matrix and a BP stabilizer, thereby improving anti-tumor efficacy and reducing drug resistance.
Resumen de: AU2025251576A1
A treatment for patients with GRIN disorder comprises overexpressing a GRIN1 gene without disrupting the genome and regardless of the type of mutation.
Resumen de: AU2025236350A1
There is provided an antimicrobial composition comprising: an antimicrobial compound; and a population of metal nanoparticles. Also described is a method of producing such an antimicrobial composition, a coating or treatment for a surface or substrate comprising such an antimicrobial composition, and a medical device comprising such a coating or treatment.
Resumen de: AU2025235898A1
The disclosure provides ionizable lipids for constructing lipid nanopartides. The disclosure further provides conjugates comprising a targeting moiety conjugated to a lipid nanoparticle (LNP) encapsulating a. therapeutic agent (i.e., payload) for delivery to cells, including immune cells, hematopoietic stem cells (HSCs), or liver cells. The conjugates can be formulated in a pharmaceutical composition and can be directly administered to a patient in need thereof, for example, via in vivo administration.
Resumen de: AU2025233886A1
The disclosure provides Fab fragments that are site-selectively conjugated to the surface of a lipid nanoparticle (LNP) through the natural interchain disulfide bond between the heavy chain and the light chain (i.e., the CL-CH1 disulfide bond) to make targeted LNPs (also referred to herein as conjugates). The targeted LNPs (conjugates) produced by the methods disclosed herein can transduce specific targeted cells. Hence, the targeted LNPs are capable of delivering therapeutic payloads to cells to treat disease in a subject.
Resumen de: AU2025231951A1
A lipid nanoparticle composition for use in the delivery of a self-amplifying RNA (saRNA) construct in one or more target cells is disclosed. The lipid nanoparticle composition comprises a lipid mixture comprising at least one (ionizable) cationic lipid, at least one helper lipid, a sterol, a corticosteroid such as Dexamethasone, and a least one lipid-polyethylene glycol conjugate. The saRNA construct comprises a first open reading frame which encodes one or more non-structural proteins, and a second open reading frame operatively linked to the first open reading frame. The second open reading frame comprises a coding region which encodes one or more target proteins. In some embodiments, the target proteins comprise one or more therapeutic proteins. In some embodiments, the target proteins comprise one or more one or more Cas proteins and/or variants thereof for use in CRISPR-based gene editing.
Resumen de: WO2026218973A1
Use of a ceramide molecule in the treatment of asthma.
Resumen de: US20260325446A1
0000 A process for producing a nanoemulsion comprising polyol-free vegetable oil, using the D-phase emulsification (DPE) method and the nanoemulsion comprising polyol-free vegetable oil, pharmaceutical composition and its use as a medicine in the treatment of atopy in mammals.
Resumen de: US20260325460A1
Embodiments of the present disclosure provide novel compositions and methods for determining atomic layer deposition (ALD) coating quality and/or dissolution rates of ALD coated therapeutic agent containing particles. In certain embodiments, in vitro methods can be used to predict or project in vivo dissolution rates of ALD coated therapeutic agent-containing particles, microparticles and/or nanoparticles. In yet other embodiments, formulations disclosed herein can be used to provide improved conditions for determining ALD coating quality or composition, optimum coating layers and/or dissolution rates to release a target therapeutic agent from ALD coating layers. In accordance with these embodiments, improved coating compositions, coating cycles, coating layering and thickness can be determined for improved timed-release delivery of pharmaceutical products to a subject in need thereof.
Resumen de: US20260325453A1
0000 Polydopamine-coated nanoparticles are presented as a novel composition for intracranial delivery, designed to absorb UV photons and mitigate neuroinflammation in brain tissue. These nanoparticles feature a core that includes materials such as silica, gold, iron oxide, or polymeric micelles and are encapsulated within a polydopamine shell. Additionally, biologically active agents can be incorporated to enhance neuroprotection. Methods are provided for treating neurodegenerative diseases (e.g., Parkinson's, Huntington's, ALS, Alzheimer's) or improving glioblastoma therapy by administering the polydopamine-coated nanoparticles directly to affected brain regions via intracerebral injection, intrathecal infusion, or convection-enhanced delivery. Furthermore, the polydopamine-coated nanoparticles hold potential for pharmaceutical applications in developing medicaments targeting neuroinflammation and UV photon absorption within the central nervous system.
Resumen de: WO2026220368A1
The present application relates to a class of cationic lipid compounds for a delivery system and use thereof, and in particular, to a lipid compound, and a lipid carrier, a nucleic acid lipid nanoparticle composition, a pharmaceutical formulation, a cell, and a kit based thereon. The compound having the structure of formula (I) of the present application can be used alone to prepare a lipid carrier, or can be used together with other lipid compounds to prepare a lipid carrier. The lipid carrier has high encapsulation efficiency for the nucleic acid drug, which helps to improve the in vivo delivery efficiency of the nucleic acid drug. Moreover, the lipid carrier can also effectively deliver the nucleic acid drug to an organ where enrichment is desired, and thus has good application prospects.
Resumen de: US20260325670A1
0000 The invention provides a composition for delivering an active pharmaceutical ingredient (API) and/or active nutraceutical ingredient (ANI) to the basal ganglia of a subject in need thereof comprising a plurality of nanoparticles surface decorated with caffeine, wherein the nanoparticles comprising: at least one API or ANI, at least one emulsifier, at least one emulsifier stabilizer, at least one water miscible solvent, and at least one solid lipid matrix core; and a pharmaceutically or nutraceutically acceptable carrier. The invention further provides methods for delivering active ingredients to the to the basal ganglia of a subject in need thereof and methods for treating Parkinson's disease.
Resumen de: WO2026222127A2
Provided are nucleic acid molecules encoding polypeptides or fusion polypeptides comprising an immunoglobulin CH3 domain that has mutations that selectively promote homodimerization and reduce or prevent heterodimerization with wild type CH3 domains or with CH3 domains containing different homodimerizing mutations. This platform technology permits the co-delivery of nucleic acid molecules encoding two, three, or four different polypeptides or fusion polypeptides comprising an immunoglobulin CH3 domain to a subject in need thereof. For example, mRNAs encoding such polypeptides are formulated in a delivery vehicle and a therapeutically effective amount of such a delivery vehicle is administered to a subject in need thereof.
Resumen de: WO2026221590A1
The invention relates to an aloe vera gel formulation containing betamethasone valerate-loaded solid lipid nanoparticles developed for use in the health and pharmaceutical sectors, and in particular in eczema treatments, as well as to a production method of the same
Resumen de: US20260325459A1
0000 The present disclosure provides a biodegradable nanoparticle platform that encapsulates an oligonucleotide, such as a DNAzyme to suppress irf5 expression, which promotes macrophage polarization to an anti-inflammatory state. Herein, the ability to transfect classically activated macrophages, directly suppress IRF5 expression and downstream cytokines, and cause metabolic changes that are indicative of an alternatively activated phenotype is demonstrated. The nanoparticles disclosed herein offer a therapeutic approach to modulate inflammatory pathways in pro-inflammatory macrophages using a biodegradable and non-immunogenic platform.
Resumen de: WO2026219957A1
Provided are compositions and methods for transfecting a target cell of hematopoietic lineage, using a lipid nanoparticle (LNP) including an ionizable lipid, the LNP encapsulating a homology directed repair (HDR) template DNA comprising a gene of interest for insertion into a desired chromosomal locus of the cell.
Resumen de: US20260325457A1
0000 The present disclosure relates to water-soluble lipid nanoparticle (LNP) compositions comprising a hydrophobic small molecule encapsulated in an LNP that can be dispersed in an aqueous carrier. In certain aspects, the LNP comprises dipalmitoylphosphatidylcholine (DPPC), 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), distearoylphosphatidylethanolamine-polyethylene glycol (DSPE-PEG), and cholesterol. The LNP compositions can be used to encapsulate the hydrophobic small molecule 3-2-(4-fluorophenyl)methylimidazo2,1-bthiazol-6-yl-2H-1-benzopyran-2-one (iMDK), an inhibitor of midkine (MDK) for treatment. The LNP compositions can be administered to treat a cancer in an individual in need thereof.
Resumen de: WO2026222482A1
The present invention provides compositions comprising the Piwi-interacting RNA (piRNA), piR-37213. The compositions may include a pharmaceutical carrier and/or a lipid nanoparticle or nanoparticle delivery system. The piRNA-37213 may be encoded by a construct or carried via a vector for delivery. Also provided are methods of treating hepatocellular carcinoma by administering the compositions comprising piRNA-37213.
Resumen de: WO2026221982A2
The disclosure provides compositions, methods of treatment, and methods of making and using compositions to deliver a nucleic acid to a subject that, optionally, have reduced reactogenicity and promotes a local innate immune response in the subject while promoting an adaptive immune response to an antigen. Compositions described herein include nanoparticles, optionally including a cationic lipid, a hydrophobic core, surfactants and/or an inorganic particle, for admixing with nucleic acids encoding proteins, antibodies, immunomodulators and a microRNA binding site. Methods of using the compositions as a therapeutic vaccine and for the treatment of an infection or cancer are also provided.
Nº publicación: WO2026218097A1 22/10/2026
Solicitante:
IMMREJ INC [CA]
IMMREJ INC.
Resumen de: WO2026218097A1
In general, in an aspect, methods and compositions of cancer immunotherapy are disclosed herein. Methods include administration of two or more immunotherapies to a subject where at least one immunotherapy provokes an anti-infection cell response within a tumor or at distant metastatic sites, such that the administered immunotherapies have a synergistic anticancer effect in a subject. Compositions include novel therapeutic or prophylactic agents that present at least a portion of an infectious microorganism indicium efficient to prime T cells against cancer cells (in a tumor or at distant metastatic sites) to that indicium.
BOPI
Sede Electrónica
